Clinical Assessment of Thrombosis in Children After Heart Surgery (CATCH)

January 29, 2016 updated by: Brian McCrindle, The Hospital for Sick Children

Clinical Assessment of Thrombosis in Children After Heart Surgery: The CATCH Study

Thromboembolic complications (TCs) are important causes of morbidity and mortality after pediatric cardiac surgery, resulting in longer hospital stay, increased risk of early and late post-surgical complications, early reoperation, neurologic and organ damage, and potentially death. The true incidence of blood clots in pediatric surgical patients is unknown.

The overarching objective of this study is to further our understanding of TCs, including quantification, characterization and risk stratification. This study will ultimately allow the development of effective tools for prevention and early identification of TCs, rather than focusing on treatment alone.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

There is very limited data on TCs associated with cardiac surgery in pediatric patients. The actual incidence of TCs in this context is not currently known reflecting a lack of clinical suspicion, reporting biases, and/or the use of inappropriate diagnostic tests

Pediatric cardiac surgery is associated with disruption of blood flow, platelet dysfunction and activation, and blood hypercoagulability; all of which are contributing to clot formation

All congenital heart defects are associated with blood flow disturbance but some are associated with more extreme disturbances. The investigators hypothesize that not all types of CHD repairs will be at the same risk of TCs based on the extent of blood flow disturbances they cause. The investigators hypothesize that line location, difficulties in line insertion, including multiple insertion attempts and longer duration of indwelling will be associated with increased risk of TCs.

Pediatric cardiac surgery is associated with inflammation and platelet activation, both of which are potent contributors to blood hypercoagulability: CPB presents a hemostatic challenge associated with an abundance of pro-thrombotic risk factors and an opposite presence of pro-hemorrhagic risk factors. The investigators hypothesize that factors associated with increased platelet activation and inflammation, and in consequence, greater laboratory values of markers of platelet activation and inflammation, will be associated with increased risk of TCs.

Coagulation system activity in children is immature, hyporeactive and exhibits a high degree of resistance to heparin and anticoagulation. The investigators theorize that lower levels of coagulation system activity, presence of high-risk genetic polymorphisms, greater CPB hemodilution, increased heparin requirement and lower blood heparin activity expressed by anti-factor X activity (anti-Xa) concentration during CPB and greater requirement for allogeneic blood will be associated for increased risk of TCs.

There is a lack of consensus on clinical and laboratory signs/symptoms of active thrombosis and on which patients should be routinely screened for TCs. One of the most difficult aspects in the management of TCs is the fact that many episodes are asymptomatic or have non-specific symptoms. Creating a risk stratification model including both clinical and laboratory abnormalities which could be indicative of TCs in the post-operative period in order to identify patients who should undergo more targeted screening is the third aim of this study.

Many methods of TC management have limited effectiveness while highly effective methods are often associated with much risk. The use of thrombolytics in children is rare and only partially effective in many cases. The margin of safety for treatment is thought to be very narrow; the reported frequency of major bleeding episodes varies from 5% to 40%.

Outcomes of TCs are suboptimal, early surgical and long-term complications for survivors are frequent. The creation of risk stratification models for suboptimal surgical outcomes, PTS syndrome and, lower functional health status after surgery will be the fourth and final aim of this study.

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 18 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Children Undergoing Pediatric Heart Surgery at the Hospital for Sick Children who agree to participate in the CATCH research study.

Description

Inclusion Criteria:

  • Pediatric patients scheduled for cardiac surgery requiring cardiopulmonary Bypass

Exclusion Criteria:

  • Known severe risk factors to thromboembolic complications
  • Active cancer
  • Congenital coagulopathy (e.g. haemophilia)
  • No planned cardiology follow-up at the Hospital for Sick Children

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Children undergoing heart surgery
The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Thromboembolic Complications (TC) after pediatric cardiac surgery
Time Frame: Outcome will be recorded throughout the duration of the participants hospital stay, an expected average of 10 days
Thrombosis will be recorded through review of post-operative clinical assessments, targeted laboratory testing for blood abnormalities and echocardiographic/ultrasound evaluation.
Outcome will be recorded throughout the duration of the participants hospital stay, an expected average of 10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of the patients' coagulation, hemostatic and inflammatory system activity
Time Frame: Baseline
Standard coagulation panel to assess the function of the coagulation system in order to identify the degree of maturity, potential for resistance to anticoagulation and overall activity of the coagulation system.
Baseline
Genome-Wide Association Study (GWAS)
Time Frame: Baseline
To identify genetic polymorphisms associated with coagulation system activity, sensitivity and overall thrombotic risk.
Baseline
Post-operative sign and symptoms of thrombosis
Time Frame: Up to 10 days after surgery
Daily clinical assessment of signs and symptoms of thrombosis
Up to 10 days after surgery
Post-thrombotic Syndrome (PTS) Evaluation
Time Frame: Up to 2 years after surgery
Assessment of upper and lower limbs based on the adaptation of the Khule scale. PTS will be classified as mild, moderate and severe.
Up to 2 years after surgery
Neurodevelopment and functional health assessment
Time Frame: Up to 2 years post- surgery
Subject will undergo Ages and Stages (ASQ, Child Health Questionnaires and PedsQL)
Up to 2 years post- surgery
Response of the patients coagulation, hemostatic and inflammatory system activity to cardiopulmonary bypass
Time Frame: Up to 10 days after surgery
Repeat of complete blood count, inflammatory markers, coagulation and fibrolnolytic systems activity
Up to 10 days after surgery
Proportion of patients with thrombo-occlusive complications of thrombosis
Time Frame: 18-24 months after surgery

Following events associated with thrombosis:

  • Death / cardiorespiratory arrest associated with thrombosis
  • Embolism (cardioembolic stroke, pulmonary embolism)
  • Obstruction (sinovenous stroke, SVC syndrome)
  • Unanticipated procedures directed at thrombosis or its clinical impact
  • Escalation of antithrombotic treatment
18-24 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brian W McCrindle, MD, The Hospital for Sick Children, Toronto Canada

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2011

Primary Completion (ACTUAL)

November 1, 2014

Study Completion (ACTUAL)

December 1, 2015

Study Registration Dates

First Submitted

September 8, 2011

First Submitted That Met QC Criteria

September 15, 2011

First Posted (ESTIMATE)

September 16, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

February 1, 2016

Last Update Submitted That Met QC Criteria

January 29, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thrombosis

Clinical Trials on Cardiac Surgery

3
Subscribe